Scope 2018

TriNetX releases new algorithm to aid clinical trial patient identification

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/tonivaver)
(Image: Getty/tonivaver)

Related tags: Cancer, Oncology, Clinical trial

The global health research network TriNetX has developed a new chemotherapy lines of treatment identification algorithm to help researchers identify potential clinical trial patients.

The new algorithm is able to understand treatment patterns to deduce a patient's line of chemotherapy treatment, according to TriNetX, which announced the new offering at the SCOPE Summit last week in Orlando, FL.

“In clinical studies, researchers are probably looking at patients that are on their second or third or maybe even fourth line of treatment, as potential candidates for trials​,” explained Jennifer Haas, vice president of marketing, TriNetX.

The offering is the latest component of TriNetX’s platform, which provides users with de-identified patient data integrated from EMRs, tumor registries, unstructured pathology reports, and molecular genomics data. This information is mapped onto the company’s network and is available for query, enabling users to analyze patient populations and perform "what-if"​ analyses, the company explained.

As sponsors and CROs are going to look up and run their queries across our platform they now can leverage [the new] algorithm​,” Haas told us at the summit.

Also of particular interest to oncology research, Haas explained the platform’s “rate of arrival​” capabilities use predictive analytics to estimate the number of patients potentially available at a later date.

That’s really helpful when designing protocols, because you then know that there will still be a cohort that you could potentially recruit​,” she added.

TriNetX also this week announced that the Boston Children’s Hospital has joined its global health research network.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars